# Intranasal Inhalations of M2 Macrophage Soluble Factors in Children With Developmental Speech Disorders

> **NCT04689282** · PHASE1,PHASE2 · COMPLETED · sponsor: **Russian Academy of Medical Sciences** · enrollment: 14 (actual)

## Conditions studied

- Language Delay
- Language; Developmental Disorder, Expressive
- Language; Developmental Disorder, Receptive
- Autism Spectrum Disorder
- Attention Deficit-Hyperactivity Disorder
- Speech Disorders in Children

## Interventions

- **BIOLOGICAL:** Bioactive Factors, Produced by M2 Type Macrophages (M2-BFs).

## Key facts

- **NCT ID:** NCT04689282
- **Lead sponsor:** Russian Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-02-01
- **Primary completion:** 2021-09-01
- **Final completion:** 2021-09-01
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2022-05-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04689282

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04689282, "Intranasal Inhalations of M2 Macrophage Soluble Factors in Children With Developmental Speech Disorders". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04689282. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*